Ming-Chao Tsai
Overview
Explore the profile of Ming-Chao Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuo Y, Chen Y, Tsai M, Lu S, Hu T, Hung C, et al.
Am J Cancer Res
. 2025 Mar;
15(2):811-823.
PMID: 40084378
Atezolizumab plus bevacizumab (Ate/Bev) and lenvatinib (Len) are first-line therapies for unresectable hepatocellular carcinoma (uHCC). However, Ate/Bev's high cost limits its common use in real-life practice, while Len is usually...
2.
Chang Y, Tsai M, Tsai C, Wang C, Lin C, Yen Y, et al.
Am J Cancer Res
. 2024 Nov;
14(10):4979-4988.
PMID: 39553207
Microscopic vascular invasion (MVI) has been demonstrated as a strong risk factor associated with tumor recurrence and poor overall survival among hepatocellular carcinoma (HCC) patients after resection, but the preoperative...
3.
Huynh C, Tsai Y, Tsai M, Tsai C, Wang C, Lin C, et al.
Am J Cancer Res
. 2024 Oct;
14(9):4567-4579.
PMID: 39417195
In 2023, a new nomenclature, metabolic dysfunction-associated steatotic liver disease (MASLD), replaced the term non-alcoholic fatty liver disease (NAFLD). With the global rise in MASLD prevalence, concurrent MASLD and chronic...
4.
Tsai Y, Tai W, Liang C, Wu C, Tsai M, Hu W, et al.
J Microbiol Immunol Infect
. 2024 Oct;
58(1):62-69.
PMID: 39393964
Background: The inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC) is a complex disease with multifactorial etiology. The intestinal dysbiosis have been investigated to play an...
5.
Yen Y, Kee K, Hu T, Tsai M, Kuo Y, Li W, et al.
PLoS One
. 2024 Mar;
19(3):e0290523.
PMID: 38489301
Background: Whether the etiology of chronic liver disease (CLD) impacts the overall survival (OS) of patients with hepatocellular carcinoma (HCC) remains unclear. We aim to clarify this issue. Materials And...
6.
Cho W, Wang C, Tsai M, Lin C, Yen Y, Chen C, et al.
Clin Med Insights Oncol
. 2024 Mar;
18:11795549241228232.
PMID: 38450293
Background: The risk of first recurrence of hepatocellular carcinoma (HCC) within years 5 to 10 after curative hepatectomy remains unknown. We aimed to assess the incidence and prognostic factors for...
7.
Carter J, Tsai M, Venturini N, Hu J, Lemasters J, Torres Martin M, et al.
Hepatology
. 2024 Feb;
80(3):566-577.
PMID: 38373106
Background And Aims: Sustained inflammation and hepatocyte injury in chronic liver disease activate HSCs to transdifferentiate into fibrogenic, contractile myofibroblasts. We investigated the role of protocadherin 7 (PCDH7), a cadherin...
8.
Hsiao Y, Sou F, Wang J, Chen Y, Tsai M, Hu T, et al.
Kaohsiung J Med Sci
. 2023 Oct;
39(12):1233-1242.
PMID: 37843189
Lenvatinib has been approved as one of the first-line treatments for advanced hepatocellular carcinoma (HCC) due to its high treatment efficacy being non-inferior to sorafenib. Previous studies have shown well-controlled...
9.
Yang S, Hu T, Chou Y, Kuo Y, Tsai M, Chang K, et al.
J Infect Public Health
. 2023 Oct;
16(11):1852-1859.
PMID: 37837921
Background: Prophylaxis antiviral therapy is recommended for patients with hepatitis B receiving chemotherapy but the ideal treatment duration after chemotherapy cessation needs more evidence for clarification. Aims: This study aimed...
10.
Kuo Y, Huang T, Yen Y, Lu S, Wang J, Hung C, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370766
Our objective was to develop a predictive nomogram that could estimate the long-term survival of patients with very early/early-stage hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA). For this retrospective study,...